Schrödinger swings to $187.1 million 2024 net loss; full-year revenue falls 4.2%
Schrödinger reported fourth-quarter and full-year 2024 results and gave 2025 guidance. Full-year total revenue fell 4.2% to $207.5 million, with software revenue up 13.3% and drug discovery revenue down 53%, and the company posted a $187.1 million net loss after 2023 net income of $40.7 million. For shareholders, the results mix growing software sales and a higher fourth-quarter revenue total with wider losses and a sharply lower drug discovery contribution.
Key points
- Full-year software revenue rose 13.3% to $180.4 million, while drug discovery revenue fell 53% to $27.2 million.
- Full-year net loss was $187.1 million, compared with net income of $40.7 million in 2023; 2023 included a $147.2 million gain on equity investments.
- Fourth-quarter total revenue rose 19.1% to $88.3 million, but the fourth-quarter net loss widened to $40.2 million from $30.7 million.
- For 2025, the company expects software revenue growth of 10% to 15% and drug discovery revenue of $45 million to $50 million.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.